Author(s):
Prakash P. Sorate, Suresh G. Killedar, Rushikesh A. Mule
Email(s):
sorateprakash08@gmail.com
DOI:
10.52711/2231-5691.2026.00063 
Address:
Prakash P. Sorate1*, Suresh G. Killedar2, Rushikesh A. Mule3
1Research Scholar, Anandi Pharmacy College, Kalambe Tarf Kale, Karavir, Maharashtra, India.
2Principal, Anandi Pharmacy College, Kalambe Tarf Kale, Karavir, Maharashtra, India.
3Student, V P College of Pharmacy, Madkhol, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Memory is an essential cognitive ability that facilitates the storage, processing, and retrieval of information vital for learning and adaptive actions. Memory impairments are frequently noted in aging and neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and various types of dementia. While traditional pharmacological treatments such as donepezil and piracetam provide therapeutic advantages, they frequently come with side effects and limited effectiveness over time. Conversely, herbal therapies, grounded in traditional healing practices such as Ayurveda and Traditional Chinese Medicine, have received increased interest because of their safety, cost-effectiveness, and capacity to function through various mechanisms. Plants like Bacopa monnieri, Withania somnifera, Centella asiatica, and Ginkgo biloba have shown promise in enhancing learning and memory via antioxidant properties, anti-inflammatory effects, and modulation of cholinergic activity. This review examines various memory types and their deficits, experimental behavioral models for evaluating cognition, and the biochemical and molecular mechanisms affected by herbal treatments. Despite the promising evidence, issues related to standardization, bioavailability, and clinical validation must still be resolved for their successful incorporation into contemporary neurotherapeutic approaches.
Cite this article:
Prakash P. Sorate, Suresh G. Killedar, Rushikesh A. Mule. Evaluation of Memory Enhancing Activity of different Herbs using Experimental Models. Asian Journal of Pharmaceutical Research. 2026; 16(4):428-6. doi: 10.52711/2231-5691.2026.00063
Cite(Electronic):
Prakash P. Sorate, Suresh G. Killedar, Rushikesh A. Mule. Evaluation of Memory Enhancing Activity of different Herbs using Experimental Models. Asian Journal of Pharmaceutical Research. 2026; 16(4):428-6. doi: 10.52711/2231-5691.2026.00063 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-4-10
11. REFERENCES:
1. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013; 6(1): 41–7.
2. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011; 10(7): 507–19.
3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity. Nat Rev Drug Discov. 2010;9(3):203–14.
4. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–49.
5. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005;10(2):139–47.
6. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening. Nat Rev Drug Discov. 2011;10(3):188–95.
7. Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs. Nat Rev Drug Discov. 2014;13(8):577–87.
8. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, et al. Large-scale prediction of drug activities. Nature. 2012;486(7403):361–7.
9. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL database update. Nucleic Acids Res. 2012;40(D1):D1100–7.
10. Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, et al. Therapeutic target database update. Nucleic Acids Res. 2016;44(D1): D1069–74.
11. Hopkins AL. Network pharmacology. Nat Chem Biol. 2008;4(11):682–90.
12. Li S, Zhang B. Systems pharmacology approaches. Exp Rev Mol Med. 2013;15: e17.
13. Martínez-Jiménez F, Papadatos G, Yang L, Wallace IM, Kumar V, Prathipati P, et al. Drug discovery data: big data challenges. Drug Discov Today. 2018;23(11):1921–6.
14. Cohen ML. Changing patterns of drug development. Nat Rev Drug Discov. 2002;1(12):932–4.
15. Kola I, Landis J. Failures in drug discovery. Nat Rev Drug Discov. 2004;3(8):711–6.
16. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry. Clin Pharmacol Ther. 2016;97(3):263–70.
17. Mullard A. New drug approvals. Nat Rev Drug Discov. 2019;18(2):85–9.
18. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97–113.
19. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning. Nat Rev Drug Discov. 2019;18(6):463–77.
20. King ZA, Draeger A, Ebrahim A, Sonnenschein N, Lewis NE, Palsson BO. Biochemical databases and in silico biology. Nat Rev Genet. 2015;16(9):538–51.
21. Mullard A. 2018 FDA drug approvals. Nat Rev Drug Discov. 2019;18(2):85–9.
22. Arrowsmith J. Trial watch: phase II failures. Nat Rev Drug Discov. 2011;10(5):328–9.
23. Arrowsmith J, Miller P. Phase III failures. Nat Rev Drug Discov. 2013;12(10):745–6.
24. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. Industry attrition rates. Nat Rev Drug Discov. 2015;14(7):475–86.
25. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Impact of innovation on drug projects. Nat Rev Drug Discov. 2018;17(3):167–81.
26. Howes LM. Regulation of drug development. Clin Pharmacol Ther. 2020;108(1):35–8.
27. U.S. Food and Drug Administration. Guidance for Industry: Drug Development. FDA; 2020.
28. Antunes M, Biala G. The novel object recognition memory test. Cogn Process. 2012; 13:93–110.
29. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, et al. Object recognition test. Nat Protoc. 2013;8(12):2531–7.
30. Klinkenberg I, Blokland A. Scopolamine as a model for cognitive impairment. Neurosci Biobehav Rev. 2010; 34:1307–50.
31. Zarrindast MR, Rostami P, Zavoshy R. Diazepam and memory retention. Acta Med Iran. 2002; 40:7–10.
32. Lukoyanov NV, Paula-Barbosa MM, Cadete-Leite A. Chronic ethanol effects. Physiol Behav. 1999; 66:337–46.
33. Stewart C, Reid IC. ECS and synaptic plasticity. Neurosci Biobehav Rev. 2000; 24:645–66.
34. Butterfield DA, Halliwell B. Oxidative stress and Alzheimer disease. Nat Rev Neurosci. 2019; 20:148–60.
35. Francis PT, Palmer AM, Snape M, Wilcock GK. Cholinergic hypothesis. J Neurol Neurosurg Psychiatry. 1999; 66:137–47.
36. Ellman GL, Courtney KD, Andres V, Featherstone RM. Rapid colorimetric AChE assay. Biochem Pharmacol. 1961; 7:88–95.
37. Sultana R, Perluigi M, Butterfield DA. Lipid peroxidation & neurodegeneration. Mol Aspects Med. 2013; 34:1217–23.
38. Numakawa T, Odaka H, Adachi N. BDNF and stress actions. Int J Mol Sci. 2017; 18:2312.
39. Querfurth HW, LaFerla FM. Alzheimer’s disease review. N Engl J Med. 2010; 362:329–44.
40. Kiernan JA. Histological and histochemical methods. 4th ed. Scion Publishing; 2008.
41. Sofroniew MV, Vinters HV. Astrocytes biology and pathology. Acta Neuropathol. 2010; 119:7–35.
42. Howes MJR, Perry E. Phytochemicals for dementia. Drugs Aging. 2011; 28:439–68.
43. Dhingra D, Parle M, Kulkarni SK. Glycyrrhiza glabra memory effects. J Ethnopharmacol. 2004; 91:361–5.
44. Joseph JA, Shukitt-Hale B, Casadesus G. Fruit polyphenols and aging. Am J Clin Nutr. 2005; 81:313S–6S.
45. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Bacopa extract on cognition. J Altern Complement Med. 2008; 14:707–13.
46. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. Curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005; 2:131–6.
47. Kennedy DO, Scholey AB. Ginseng cognitive effects. Pharmacol Biochem Behav. 2003; 75:687–700.
48. Kumar V. Medicinal plants and cognition. Indian J Nat Prod Resour. 2014; 5:213–21.
49. Yuan H, Ma Q, Ye L, Piao G. Traditional vs modern herbal medicine. Molecules. 2016; 21:559.
50. Ekor M. Safety issues in herbal medicine. Front Pharmacol. 2014; 4:177.
51. Williamson EM, Liu X, Izzo AA. Herbal medicines: trends and clinical applications. Clin Pharmacol Ther. 2020; 107:837–49.